EAU 2017: Perioperative chemotherapy does not improve disease free survival in upper tract urothelial carcinoma: a population based analysis
London, England (UroToday.com) Upper tract urothelial carcinoma (UTUC) is a rare disease, accounting for less than 5% of all urothelial cancers and with a peak incidence in the 8th and 9th decade. The role of perioperative chemotherapy remains poorly defined. Current practice in UTUC is derived from evidence related to muscle-invasive bladder cancer, where it has been shown to have a positive effect on cancer specific survival (CSS).
EAU 2017: State-of-the-art Lecture: How will Immunotherapy Change the Treatment Paradigm?
London, England (UroToday.com) Dr. Robert Jones from Glasgow presented the role of immunotherapy in the current treatment paradigm of bladder urothelial carcinoma.
EAU 2017: State-of-the-art Lecture: Is There Still a Role for Chemotherapy?
London, England (UroToday.com) Dr. Aristotle Bamias from Greece had the important role of delivering the State-of-the-Art Lecture on “Is There Still a Role for Chemotherapy?” for bladder urothelial carcinoma in the era of Immuno-oncology at today’s EAU 2017 annual congress.
EAU 2017: Updated meta-analysis (MA) of salvage therapy for metastatic urothelial cancer (mUC): Comparing outcomes of immunotherapy (IT) vs. single agent and doublet chemotherapy (CT)
London, England (UroToday.com) The management of metastatic urothelial carcinoma is undergoing rapid changes. With the introduction of immunotherapy, chemotherapy is no longer the only option.
EAU 2017: State of the Art Lecture: Enhanced recovery after surgery (ERAS) for bladder cancer: non-surgical options to improve outcomes of cystectomy
London, England (UroToday.com) In this session, Professor Catto discussed non-surgical options for improving outcomes of cystectomy. Radical cystectomy is a morbid operation with 64% of patients having any complication, 13% having a major complication, and 20% being readmitted after surgery.
EAU 2017: State of the Art Debate - Evidence for extent of lymphadenectomy in urothelial bladder cancer
London, England (UroToday.com) In this session, Professor Witjes discussed the state of the evidence for lymphadenectomy in bladder cancer. He began by quoting Dr. Skinner who believed that the patients who benefit the most from LND had low volume micrometastic disease.
EAU 2017: Debate - Do we need to follow-up in low grade bladder tumor after 12 months?-Yes (EAU Guidelines)
London, England (UroToday.com) In this session, a debate ensued between two guidelines for the surveillance of low risk bladder tumors. Specifically, what is the best follow-up protocol for low risk tumors that do not recur? Is it 1 year as the NICE guidelines would suggest or 5 years as the EAU guidelines would suggest? Professor Burger was tasked with defending the EAU guideline recommendations of 5 years of total follow-up.